Colchicine plus fosfomycin in coronavirus infection

Claudio Gustavo Cerati  Pharmacist ,  University of Buenos Aires ,Argentina.
Polymericaps

Title:
Colchicine plus fosfomycin in coronavirus infection
Authors:
Cerati Claudio

Abstract
Some antibiotics can act as immunomodulators and particularly fosfomycin has an immunomodulatory effect on human B-cell activation. Fosfomycin is considered a unique antibiotic that is chemically unrelated to any other known antibacterial agent. The effect of fosfomycin on human T-cells function was yet studied along with the inhibition of proliferation of human lymphocytes induced by polyclonal T-cell mitogens as a function of fosfomycin dose.

Colchicine is an ancient API with known benefits in several diseases like FMD (Familial Mediterranean Fever) and gout presenting narrow therapeutic margin and side effects when administered orally. Delivering both Colchicine and Fosfomycin by inhalation, transdermal and intranasal route was the objective of the present study.

Introduction
It was also described the suppression by fosfomycin of mixed lymphocyte reaction and interleukin-2 (IL-2) production by T cells along with the expression of IL-2 receptor (CD25) on the activated T-cell surfaces. Previous research demonstrated that fosfomycin blocks T-cell division during the transition from G1 to S phase of the cell cycle.

Materials and Methods
Both Colchicine USP 29-NF 24 (crystalline) and Fosfomycin (sodium ) USP grade were used. Micro and nanoencapsulation was carried on using polymers accepted for injectable dosage forms. Colchicine and fosfomycin micro and nanocapsules were vehiculized in an appropriate vehicle (water for injection) as used for inhalation route (0.5 mg colchicine/ 50 mg fosfomycin per dose) and also vehiculized in a silicone matrix intended for the controlled release of colchicine (0.5 mg/day/20 day period).

Results
1. Colchicine and fosfomycin were micro-encapsulated separately or co-encapsulated in bi-layered spheres (Fig 1) in order to obtain a uniform dose and stable suspension of the particles in the vehicle for inhalation.

2. Evidence was provided about SARs-CoV-2 infection of brain tissue, consistent with its multiorgan involvement and viral entry into the brain through the olfactory epithelium. (Ref1)

2.1 Differential spreading in the CNS could be due to interactions between the spike protein involved in anterograde and retrograde movement along the microtubule tracks, as seen in some human neurotropic viruses.

2.2 Disruption of microtubules with colchicine significantly blocks neuronal transport and reduces viral replication. The reduction of viral titer was due to reduced viral spread through neuron, and not due to cytotoxicity caused by colchicine. (Ref 2)

2.4 Certain strains of human coronaviruses could persist in the human CNS by targeting oligo-dendrocyte and neuronal cell lines. Covid-19 targeting of the Central Nervous System (possibly via olfactory nerves), caused severe respiratory distress, strokes, impaired cognition, and brain hemorrhages.

2.5 Patients with Allergic Rhinitis exhibited increased numbers of neutrophils in peripheral blood, nasal biopsies and nasal lavage fluid during the pollen season. Activated neutrophils can help activate T cells.

2.6 Mechanisms of neuroinvasiveness involve intranasal infection and both HCoV-OC43 and SARS-CoV were shown to infect the lungs in mice and to be neuroinvasive being detected in the CNS of susceptible mice. (Ref3)

Viruses may enter the CNS through two distinct routes: hematogenous dissemination or neuronal retrograde dissemination. Reduction of viral titer was due to reduced viral spread through neuron, and not due to cytotoxicity caused by colchicine. (Fig 1)

Low colchicine concentrations such as 10 µM as inhibitor of host cell microtubule dynamics can reduce viral invasion and transport inside the cell.

3. Colchicine is a medication that acts on inflammasome NLRP3 and can reduce cytokine storm and recently, it has been recognized as an inhibitor of NLRP3 inflammasomes and mitigating interleukin activation.

3.1 In case of co-administration of multiple drugs, the risk of drug interactions increases, however, a more complex disease-drug-drug interaction is expected in Covid-19 infection as the result of high rates of hospitalization and intensive care unit (ICU) admission.

3.2 According to its manufacturer, remdesivir undergoes extensive metabolism by CYPs especially CYP3A4, moreover, other potential candidates for treating Covid-19 such as Colchicine are also hepatobically metabolized being CYP3A4 a key cytochrome in the colchicine metabolism pathway.

4. Colchicine loaded transdermal patch (10 mg / 20 days release) was prepared by nanoencapsulation following Polymicrocaps® technology and inclusion into a silicone matrix. Controlled release followed by Bromocresol green nanoencapsulated along with Colchicine API.Transdermally permeated particles through skin show blue colour.

Discussion
Bacterial and viral interactions within the nasopharynx and whole respiratory tract by coronavirus and bacteriae performs through epithelia colonization via host cell surface receptors, such as the platelet activating factor (PAF) receptor, aggregation of PAF receptor expression induced by infection with respiratory viruses, including RSV or coronavirus, results in the enhanced adherence of bacteria to respiratory epithelial cells.

Therapeutic association between fosfomycin and colchicine represent a useful option for administration through Inhalation.

Neubulization of.
Alternate routes presented for colchicine could be intranasal or transdermal.

References

1) Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. Ludovico Cantuti-Castelvetro et al. https://doi.org/10.1101/2020.06.07.1378012.

2) Effect of Microtubule Disruption on Neuronal Spread and Replication of Demyelinating and Nondemyelinating Strains of Mouse Hepatitis Virus In Vitro. Kaushiki Biswas, Jayasri Das Sarma. DOI: 10.1128/JVI.02545-13

3) Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans Marc Desorges 1, Alain Le Coupanec, Elodie Brison, Mathieu Meessen-Pinard, Pierre J Talbot PMID: 24619619 PMCID: PMC7121612 DOI: 10.1007/978-3-12-1777-0_6.